Correction to: Diabetes Ther 10.1007/s13300-019-0657-8 {#Sec1}
======================================================

In the original publication, Table 2 note was incorrectly published as "\*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m^2^. Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches \< 45 mL/min/1.73 m^2^".

The correct text should read as "\*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m^2^. Individuals already treated with an SGLT2i therapy who demonstrate renal decline may continue treatment until eGFR reaches \< 45 mL/min/1.73 m^2^."

The original article has been corrected.
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